Search
temsirolimus (Torisel)
Indications:
- renal cell carcinoma
Dosage:
- IV infusion over 30-60 minutes weekly
Adverse effects:
- allergic reactions, angioedema
- weakness, fatigue
- edema
- headache
- dysgeusia
- sore mouth or throat
- loss of appetite, weight loss
- nausea/vomiting
- constipation, diarrhea, bloody stools
- urinary frequency, dysuria, hematuria, oliguria
- back pain, myalgia, arthralgia
- epistaxis
- changes in fingernails or toenails
- dry skin
- tachycardia
- acne
- insomnia
- depression
- dyspnea, tachypnea
- dysphagia
- flushing
- chest pain
- dizziness, fainting
- new or worsening abdominal pain
- blurred vision
- dysarthria
- confusion
- focal neurologic deficit
Mechanism of action:
- protein kinase inhibitor, inhibits mTOR
- leads to cell cycle arrest in G1 phase
- inhibits tumor angiogenesis by reducing synthesis of VEGF
General
antineoplastic enzyme inhibitor
References
- PubMed Health
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000420/
- Wikipedia: Temsirolimus
http://en.wikipedia.org/wiki/Temsirolimus